Ayabudge LLC - 26 Aug 2021 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: 10%+ Owner
Signature: /s/ Ayabudge LLC by Dale A. Sander as Attorney-in-Fact
Issuer symbol: HUMA
Transactions as of: 26 Aug 2021
Net transactions value: +$15,225,000
Form type: 4
Filing time: 27 Aug 2021, 16:13:06 UTC
Next filing: 19 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HUMA	Common Stock	Award		+18,930,004			18,930,004	26 Aug 2021	Direct	F1
transaction	HUMA	Common Stock	Purchase	$15,225,000	+1,522,500	+8%	$10.00	20,452,504	26 Aug 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 26, 2021, Alpha Health care Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.

Content

On August 26, 2021, Alpha Health care Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.